Kezar Life Sciences, Inc. (NASDAQ:KZR) Expected to Post Q1 2024 Earnings of ($0.26) Per Share

Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) – Research analysts at William Blair issued their Q1 2024 earnings estimates for shares of Kezar Life Sciences in a report released on Wednesday, March 15th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of ($0.26) for the quarter. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($1.25) per share. William Blair also issued estimates for Kezar Life Sciences’ Q2 2024 earnings at ($0.25) EPS, Q3 2024 earnings at ($0.22) EPS and Q4 2024 earnings at ($0.20) EPS.

KZR has been the subject of a number of other reports. Wells Fargo & Company lowered their price target on shares of Kezar Life Sciences from $17.00 to $14.00 and set an “overweight” rating for the company in a report on Tuesday, January 3rd. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Kezar Life Sciences in a report on Thursday.

Kezar Life Sciences Price Performance

KZR opened at $3.82 on Thursday. The company has a fifty day simple moving average of $6.27 and a 200 day simple moving average of $7.32. The firm has a market cap of $261.21 million, a price-to-earnings ratio of -3.78 and a beta of 0.25. Kezar Life Sciences has a twelve month low of $3.75 and a twelve month high of $18.55. The company has a current ratio of 31.15, a quick ratio of 31.15 and a debt-to-equity ratio of 0.03.

Insiders Place Their Bets

In other Kezar Life Sciences news, major shareholder Morningside Venture Investment sold 5,000 shares of the firm’s stock in a transaction on Thursday, January 12th. The shares were sold at an average price of $6.77, for a total transaction of $33,850.00. Following the completion of the transaction, the insider now directly owns 5,881,078 shares of the company’s stock, valued at approximately $39,814,898.06. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 248,276 shares of company stock valued at $1,708,683 in the last ninety days. Corporate insiders own 7.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can acquired a new position in Kezar Life Sciences during the 3rd quarter worth $26,000. Amundi acquired a new position in shares of Kezar Life Sciences in the 4th quarter valued at about $32,000. Tower Research Capital LLC TRC boosted its holdings in shares of Kezar Life Sciences by 88.9% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,777 shares of the company’s stock valued at $58,000 after buying an additional 3,190 shares during the period. Robeco Institutional Asset Management B.V. acquired a new position in shares of Kezar Life Sciences in the 3rd quarter valued at about $68,000. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of Kezar Life Sciences in the 3rd quarter valued at about $86,000. 84.03% of the stock is owned by institutional investors and hedge funds.

Kezar Life Sciences Company Profile

(Get Rating)

Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.